Tazemetostat and Mosunetuzumab in Untreated Follicular Lymphoma
- Conditions
- Follicular Lymphoma
- Interventions
- Registration Number
- NCT05994235
- Lead Sponsor
- Weill Medical College of Cornell University
- Brief Summary
The goal of this study is to learn about the safety and effectiveness of the combination of tazemetostat pills in combination with mosunetuzumab injections for people with follicular lymphoma who haven't received treatment before. The investigators hypothesize that tazemetostat with mosunetuzumab has the potential to increase the efficacy of the product without compromising the safety.
Tazemetostat is a drug that inhibits EZH2, an enzyme known to drive the development of B-cell lymphomas, and inhibiting it appears to have many effects that slow down lymphoma growth and enhance the immune system's ability to fight it. Tazemetostat is FDA-approved in previously treated follicular lymphoma and currently undergoing study in other lymphomas.
Mosunetuzumab is a bispecific antibody therapy that is a therapeutic strategy that uses the immune system to fight lymphoma, called immunotherapy. Bispecific antibodies have two ends: one attaches to T cells in the immune system and the other attaches to lymphoma cells, helping guide our immune system to attack the cancer. Mosunetuzumab has been studied in follicular lymphoma that has previously been treated, with positive results. Mosunetuzumab is approved by the FDA to be given intravenously (directly into a vein) but is not yet approved by the FDA is not yet approved as an injection under the skin, which is how it is given in this study. They have not yet been studied in combination.
- Detailed Description
This is a phase II, open-label study. Fifty patients will be enrolled and treated with standard dosing of SC mosunetuzumab, and with oral tazemetostat by mouth twice daily at standard dosing (800 mg twice daily) beginning at the same time as mosunetuzumab initiation. Response assessments by PET/CT will occur post-mosunetuzumab at Cycle 4, Day 1 (+/- 3 days) and again at the end of treatment. If a participant has a complete response (CR) at Cycle 4 and/or cycle 8, then they will receive a total of 8 cycles of mosunetuzumab. If the patient has a partial response or stable disease at Cycle 4 and Cycle 8, then they will receive a total of 12 cycles of mosunetuzumab. All participants will receive 12 cycles of tazemetostat, unless discontinued from treatment early for disease progression or other protocol-defined reasons. Treatment with steroids, tocilizumab, growth factors, tumor lysis prophylaxis, and antibiotics may be used as per standard of care at our institution. Dose modifications are permitted for toxicity. Correlative studies will be performed prior to and following tazemetostat treatment and peripheral blood collections prior to post-mosunetuzumab treatment, which will give additional descriptive data for use in correlative analyses.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 50
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Subcutaneous Mosunetuzumab and Oral Tazemetostat Tazemetostat Pill 50 patients will be enrolled and treated with standard dosing of subcutaneous mosunetuzumab, and with oral tazemetostat by mouth twice daily at standard dosing (800 mg twice daily) beginning at the same time as mosunetuzumab initiation. Subcutaneous Mosunetuzumab and Oral Tazemetostat Mosunetuzumab 50 patients will be enrolled and treated with standard dosing of subcutaneous mosunetuzumab, and with oral tazemetostat by mouth twice daily at standard dosing (800 mg twice daily) beginning at the same time as mosunetuzumab initiation.
- Primary Outcome Measures
Name Time Method Number of participants who achieve a complete response (CR) by completion of therapy, as determined by the Lugano Criteria Estimated day 336 The proportion of patients who achieve complete response as per the Lugano criteria will be calculated and their 90% confidences will be computed with Clopper-Pearson method via exact binomial distribution.
- Secondary Outcome Measures
Name Time Method Number of participants who experience Immune effector cell-associated neurotoxicity syndrome (ICANS) Day 0 to Day 28 ICANS will be assessed per American Society for Transplantation and Cellular Therapy (ASTCT) Consensus Grading
Median Progression-Free Survival (PFS) For a maximum of approximately 10 years PFS is defined as the duration of time from start of treatment to time of progression or death from any cause. Patients will be followed for a maximum of approximately 10 years from the start of treatment.
Objective Response Rate (ORR) at the time of therapy completion, as defined by Lugano Criteria Estimated to be day 336 ORR is defined as the proportion of patients who have a partial or complete response to therapy
Number of participants who experience cytokine release syndrome (CRS) Day 0 to Day 28 CRS will be assessed per American Society for Transplantation and Cellular Therapy (ASTCT) Consensus Grading
Median Overall Survival (OS) For a maximum of approximately 10 years OS is defined as the duration of time from start of treatment to death from any cause. Patients will be followed for a maximum of approximately 10 years from the start of treatment.
Number of participants who achieve a Complete Response (CR) per Lugano's Criteria For a maximum of approximately 10 years Response and progression are evaluated according to the Lugano criteria for lymphoma response.
Median Duration of Response For a maximum of approximately 10 years The duration of overall response is measured from the time measurement criteria are met for CR or PR (whichever is first recorded) until the first date that recurrent or progressive disease or death due to any cause, whichever occurs first is objectively documented (taking as reference for progressive disease the smallest measurements recorded since the treatment started).
Trial Locations
- Locations (1)
Weill Cornell Medicine/NewYork-Presbyterian Hospital
🇺🇸New York, New York, United States